MDMA
Other ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
MDMA is not supported by NutriStack. Safety information only.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
MDMA is an other. NutriStack rates the overall evidence as insufficient. This profile indexes 15 sources.
The bottom line
Evidence rating insufficient. 15 sources indexed (2001–2026), with 0 interaction records on file.
Dosing & protocol.
What it actually costs.
Real-world pricing across three quality tiers. Assumes Not recommended / controlled substance.
No effective supplement dose exists. Cost is intentionally not modeled for this illegal non-medical substance. Updated 2026-05-28.
The same dose, as food.
How much you'd eat to match a supplemental dose.
MDMA is a psychoactive drug, not a nutrient or food-derived supplement.
Full safety detail.
Side effects
- Hyperthermia
- Hyponatremia
- Jaw clenching
- Tachycardia and higher blood pressure
- Serotonin toxicity risk with serotonergic co-use
- Low mood or fatigue after use
- Adulterant-related toxicity
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
6- 1MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs).PMIDShahrour G et al. · Neuropsychopharmacol Rep · 2024
Meta-analysis of nine trials found significant improvements in PTSD symptom severity, response, and remission rates with MDMA-assisted psychotherapy versus control.
- 2Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysisPMIDColcott J, Guerin AA, Carter O et al. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
Colcott J, Guerin AA, Carter O et al.. Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024
- 3Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysisPMIDHsu TW, Tsai CK, Kao YC et al. · BMJ (Clinical research ed.) · 2024
Hsu TW, Tsai CK, Kao YC et al.. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. BMJ (Clinical research ed.). 2024
- 4Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic reviewPMIDSarparast A, Thomas K, Malcolm B et al. · Psychopharmacology · 2022
Sarparast A, Thomas K, Malcolm B et al.. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology. 2022
- 5MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-AnalysisPMIDSmith KW, Sicignano DJ, Hernandez AV et al. · Journal of clinical pharmacology · 2022
Smith KW, Sicignano DJ, Hernandez AV et al.. MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. Journal of clinical pharmacology. 2022
- 6Decision-making in chronic ecstasy users: a systematic reviewPMIDBetzler F, Viohl L, Romanczuk-Seiferth N · The European journal of neuroscience · 2017
Betzler F, Viohl L, Romanczuk-Seiferth N. Decision-making in chronic ecstasy users: a systematic review. The European journal of neuroscience. 2017
Randomized controlled trials
5- 7Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participantsPMIDStraumann I, Avedisian I, Klaiber A et al. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
Straumann I, Avedisian I, Klaiber A et al.. Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024
- 8Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical TrialsPMIDAtila C, Straumann I, Vizeli P et al. · JAMA network open · 2024
Atila C, Straumann I, Vizeli P et al.. Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials. JAMA network open. 2024
- 9MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialPMIDMitchell JM, Ot'alora G M, van der Kolk B et al. · Nature medicine · 2023
Mitchell JM, Ot'alora G M, van der Kolk B et al.. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature medicine. 2023
- 10MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.PMIDMitchell JM et al. · Nat Med · 2021
Phase 3 trial found MDMA-assisted therapy produced a larger reduction in PTSD severity than placebo-assisted therapy and was generally well tolerated in the trial setting.
- 11The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot studyPMIDMithoefer MC, Wagner MT, Mithoefer AT et al. · Journal of psychopharmacology (Oxford, England) · 2011
Mithoefer MC, Wagner MT, Mithoefer AT et al.. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of psychopharmacology (Oxford, England). 2011
Reviews & position papers
4- 123,4-Methylenedioxymethamphetamine (MDMA) ToxicityPMIDFigurasin R, Lee VR, Maguire NJ · 2026
Figurasin R, Lee VR, Maguire NJ. 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity. 2026
- 13MDMA and the Brain: A Short Review on the Role of Neurotransmitters in NeurotoxicityPMIDMustafa NS, Bakar NHA, Mohamad N et al. · Basic and clinical neuroscience · 2020
Mustafa NS, Bakar NHA, Mohamad N et al.. MDMA and the Brain: A Short Review on the Role of Neurotransmitters in Neurotoxicity. Basic and clinical neuroscience. 2020
- 14MDMA interactions with pharmaceuticals and drugs of abusePMIDPapaseit E, Pérez-Mañá C, Torrens M et al. · Expert opinion on drug metabolism & toxicology · 2020
Papaseit E, Pérez-Mañá C, Torrens M et al.. MDMA interactions with pharmaceuticals and drugs of abuse. Expert opinion on drug metabolism & toxicology. 2020
- 15The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.PMIDKalant H · CMAJ · 2001
Review documents sympathomimetic toxicity, hyperpyrexia, rhabdomyolysis, hyponatremia, and concerns about serotonergic neurotoxicity and fatalities.
Common questions.
Quick answers about MDMA, drawn from the data on this page.
What is MDMA?
MDMA is not supported by NutriStack. Safety information only.
What are the side effects of MDMA?
Reported side effects include hyperthermia, hyponatremia, jaw clenching, tachycardia and higher blood pressure, serotonin toxicity risk with serotonergic co-use, low mood or fatigue after use. This is educational information; check with a healthcare professional before use.
How strong is the evidence for MDMA?
NutriStack rates this as Insufficient, meaning the body of evidence reviewed in NutriStack's tiering framework. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
MDMA in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.